Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study.

Journal: The International journal on drug policy

Volume: 109

Issue: 

Year of Publication: 2022

Affiliated Institutions:  Centre for Infectious Disease Epidemiology & Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: mpho.tlali@uct.ac.za. Urban Futures Centre, Steve Biko Campus, Durban University of Technology, Durban, South Africa; TB HIV Care, th Floor, Adderley Street, Cape Town, South Africa; Community Oriented Primary Care Research Unit, Department of Family Medicine, University of Pretoria, Pretoria, South Africa. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Centre for Infectious Disease Epidemiology & Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Graduate School of Health Sciences, University of Bern, Bern, Switzerland. Centre for Infectious Disease Epidemiology & Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Abstract summary 

The use of opioids is increasing globally, but data from low- and middle-income countries on opioid-related mental and behavioural disorders (hereafter referred to as opioid-related disorders) are scarce. This study examines the incidence of opioid-related disorders, opioid agonist use, and excess mortality among persons with opioid-related disorders in South Africa's private healthcare sector.We analysed longitudinal data of beneficiaries (≥ 11 years) of a South African medical insurance scheme using reimbursement claims from Jan 1, 2011, to Jul 1, 2020. Beneficiaries were classified as having an opioid-related disorder if they received an opioid agonist (buprenorphine or methadone) or an ICD-10 diagnosis for harmful opioid use (F11.1), opioid dependence or withdrawal (F11.2-4), or an unspecified or other opioid-related disorder (F11.0, F11.5-9). We calculated adjusted hazard ratios (aHR) for factors associated with opioid-related disorders, estimated the cumulative incidence of opioid agonist use after receiving an ICD-10 diagnosis for opioid dependence or withdrawal, and examined excess mortality among beneficiaries with opioid-related disorders.Of 1,251,458 beneficiaries, 1286 (0.1%) had opioid-related disorders. Between 2011 and 2020, the incidence of opioid-related disorders increased by 12% (95% CI 9%-15%) per year. Men, young adults in their twenties, and beneficiaries with co-morbid mental health or other substance use disorders were at increased risk of opioid-related disorders. The cumulative incidence of opioid agonist use among beneficiaries who received an ICD-10 diagnosis for opioid dependence or withdrawal was 18.0% (95% CI 14.0-22.4) 3 years after diagnosis. After adjusting for age, sex, year, medical insurance coverage, and population group, opioid-related disorders were associated with an increased risk of mortality (aHR 2.28, 95% CI 1.84-2.82). Opioid-related disorders were associated with a 7.8-year shorter life expectancy.The incidence of people diagnosed with or treated for an opioid-related disorder in the private sector is increasing rapidly. People with opioid-related disorders are a vulnerable population with substantial psychiatric comorbidity who often die prematurely. Evidence-based management of opioid-related disorders is urgently needed to improve the health outcomes of people with opioid-related disorders.

Authors & Co-authors:  Tlali Mpho M Scheibe Andrew A Ruffieux Yann Y Cornell Morna M Wettstein Anja E AE Egger Matthias M Davies Mary-Ann MA Maartens Gary G Johnson Leigh F LF Haas Andreas D AD

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Abbafati C, Machado DB, Cislaghi B, Salman OM, Karanikolos M, McKee M, Abbas KM, Brady OJ, Larson HJ, Trias-Llimós S, Cummins S, Langan SM, Sartorius B, Hafiz A, Jenabi E, Mohammad Gholi Mezerji N, Borzouei S, Azarian G, Khazaei S, … Zhu C (2020a). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1204–1222. 10.1016/S0140-6736(20)30925-9
Authors :  10
Identifiers
Doi : 10.1016/j.drugpo.2022.103853
SSN : 1873-4758
Study Population
Male,Female
Mesh Terms
Young Adult
Other Terms
Mortality;Opioid agonist therapy;Opioid substitution therapy;Opioid use disorders;Private sector;South Africa
Study Design
Cohort Study,Longitudinal Study,Cross Sectional Study
Study Approach
Country of Study
South Africa
Publication Country
Netherlands